源于Ⅳ型胶原α3、α6链的肿瘤新生血管生成抑制剂  

Tumor Angiogenesis Inhibitors Derived from Type Ⅳ Collagen α3,α6 Chains

作　　者：唐晓[1] 宋娜玲[1] 贺欣[1] 

机构地区：[1]中国医学科学院＆北京协和医学院放射医学研究所核医学研究室,天津市分子核医学重点实验室,天津300192

出　　处：《中国生物化学与分子生物学报》2011年第10期901-906,共6页Chinese Journal of Biochemistry and Molecular Biology

基　　金：中国医学科学院放射医学研究所发展基金(No.SF1104,No.ST1113)~~

摘　　要：肿瘤抑素(Tumstatin)和Hexastatin是分别源于Ⅳ型胶原α3、α6链的肿瘤新生血管生成抑制剂.肿瘤的发生、发展和转移都依赖于新生血管的生成.通过抑制肿瘤新生血管的生成,阻断肿瘤细胞赖以生存的氧气及营养供给,肿瘤细胞便会发生凋亡.这是肿瘤治疗的新策略.Tumstatin和Hexastatin是近年来研究比较多的两种肿瘤新生血管生成抑制剂,其中Tumstatin的结构、活性位点、抑制肿瘤新生血管形成机制研究得比较清晰;Hexastatin虽与Tumstatin有许多相似之处,但是还有很多问题需要进一步研究解决.该文就这两种肿瘤新生血管生成抑制剂等的最新研究进展做一综述.Tumstatin and Hexastatin are two tumor angiogenesis inhibitors derived from type Ⅳ collagen α3,α6 chains,respectively.The emergence,progress and metastasis of tumors rely on the generation of new blood vessel.If tumor cells are cut off the supply of oxygen and nutrition through inhibiting new angiogenesis,they will lead to apoptosis.This is the new strategy of tumor therapy in recent years.Tumstatin and Hexastatin are the hot research points among the tumor angiogenesis inhibitors.Meanwhile,the study of Tumstatin goes further and clearer,such as its structure,active site,and mechanism of inhibiting tumors angiogenesis.Hexastatin is a new finding tumor angiogenesis inhibitor.Although Hexastatin has many common characteristics with Tumstatin,a number of problems remain to be studied and solved.In this paper,the new research progress of Tumstatin and Hexastatin will be reviewed.

关 键 词：肿瘤抑素 Hexastatin 肿瘤新生血管生成抑制剂 

分 类 号：R73[医药卫生—肿瘤] Q78[医药卫生—临床医学]